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Background: P53 is a tumor suppressor protein that acts to regulate the cell cycle and, 
therefore, regulate cell division processes and cell death processes. P53 mutations are 
classified as either contact mutations, where changes are found in the residues that 
contact with DNA, or structural mutations, where changes cause either a full or partial 
distortion of the conformation. Certain “hotspot” mutations have been identified, and 
these abolish the functionality of p53 as a tumor suppressor. P53’s function as a tumor 
suppressor is two-fold. It induces cellular apoptosis and affects the cell cycle. The 
DREAM complex (dimerization partner, RB-like, E2F and multi-vulval Class B 
complex) works by repression of gene expression or activation of gene expression. 
Indirectly, p53 activates this DREAM complex to repress cell cycle genes by replacing 
the activating complex. Human pituitary adenomas, the second most common intracranial 
tumors, usually form from different cell types in the anterior pituitary. If these adenomas 
secrete a pituitary hormone (GH, PRL, ACTH, or TSH), they are termed clinically 
functioning. If not, they are deemed clinically nonfunctioning. Pituitary tumors have a 
diverse genetic background, which include germline genetic defects, tumor genetic 
defects, and somatic genetic changes. Human pituitary carcinomas are much more rare 
than pituitary adenomas, and they are only usually diagnosed due to the pituitary tumor 
being noncontiguous with the sella turcica region and/or metastasis of the pituitary tumor. 
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Because of the rarity of these, the genetics of these tumors is not well-documented, and 
the plan of treatment is diverse. In particular, corticotropic tumors are pituitary adenomas 
or pituitary carcinomas that are either clinically functioning, which secrete 
adrenocorticotropin (ACTH), or silent, which do not secrete ACTH. If the tumor is 
functioning, many patients have symptoms of Cushing’s disease (CD) due to the 
hypersecretion of ACTH, which triggers an increase in hormone production downstream 
hormone production.  
Objective: This thesis seeks to describe a cohort of patients with functional corticotropic 
tumors and patients with silent (nonfunctioning) corticotropic tumors. In this cohort of 
patients, this thesis strives to find the gene mutations in this cohort to find a correlation 
between TP53 gene mutations that would affect the functionality of the p53 protein and 
the formation of corticotropic adenomas. 
Methods: A total of 38 tumor samples from 36 patients between the ages of 20 and 79 
were studied for somatic mutations. By way of whole-exome sequencing with normal 
DNA pairs, somatic mutations for each of the samples were determined. Along with 
somatic mutations, some samples were sequenced for germline mutations. RNA 
sequencing was completed to find somatic mutations and check the gene expression and 
gene transcription to compare to the somatic mutations found by way of whole-exome 
sequencing. Each of the somatic mutations found for TP53 were verified by ClinVar and 
COSMIC databases. 
Results: From whole-exome sequencing, three samples out of the 38 samples were found 
to contain somatic mutations in the TP53 gene. In sample 29, two missense somatic 
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mutations were found. First, in codon 743 (c.943G>A), this mutation produced the 
variant p53 protein, R248Q, a “hotspot” mutation. Second, in codon 523 (c.523C>T), this 
mutation produced the variant p53 protein, R175C. In sample 30, a missense mutation 
was found in codon 641 (c.641A>G), which produced the variant p53 protein, H214R. 
Last, in sample 36, a splice donor mutation was found in nucleotide 993 (c.993+1G>A), 
the variant located on intron 9 altered the consensus splice donor site. This resulted in an 
inclusion on intron 9 between exon 9 and exon 10, which produces a disrupted p53 
protein. 
Conclusion: No patients with Cushing’s disease were found to have TP53 mutations, and 
3 out of the 14 patients classified as silent corticotrophs had somatic mutations in the 
TP53 gene. Due to finding three patients that have a somatic mutation in the TP53 gene, 
and that, in each of these cases, the pituitary adenomas are all silent and aggressive, we 
can conclude that there is a correlation between TP53 gene mutations that produce an 
ineffective p53 protein and the formation of aggressive corticotropic adenomas.  
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P53 and the Cell Cycle 
 P53, named the Guardian of the Genome by Strachan and Read, is a tumor 
suppressor protein that acts to regulate the cell cycle and, therefore, regulate cell division 
processes and cell death processes (Strachan & Read, 1999). Encoded by the TP53 gene, 
p53 protein genetic code in the human genome resides on Chromosome 17 (Oliveira et 
al., 2002). As a phosphoprotein transcription factor, p53 is responsible for the regulation 
of hundreds of genes, which, in turn, function to mediate p53-dependent functions 
(Innocente et al., 1999; Liu et al., 2010). The loss of p53 functionality can occur by way 
of mutation or other mechanisms. This loss is associated with an increased susceptibility 
to tumorigenesis. This tumorigenesis is spontaneous and carcinogen-induced due to two 
of p53’s functions as a tumor-suppressor, induction of apoptosis and cell cycle arrest 
(Engeland, 2018; Innocente et al., 1999). As such, in over 50% of all progressions of 
cancers, somatic mutations of TP53 are to blame (Liu et al., 2010).  
Of these mutations to TP53, missense mutations within the DNA-binding core 
domain are the most common (Liu et al., 2010). All the mutations with regard to p53 can 
be divided into two general classes. The first of these are DNA contact mutations, which 
only change the residues that are directly involved with DNA binding (Liu et al., 2010; 
Stein et al., 2019). The second of these mutation classes is defined as structural 
mutations, which dramatically change the conformation of p53. (Liu et al., 2010; Stein et 
al., 2019) These mutations can cause either a full or partial distortion of the correct 
folding (Liu et al., 2010; Stein et al., 2019). So-called “hotspot” mutations are found in 
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both of these two classes. “Hotspot” mutations include contact mutations such as R248W 
and R173H and structural mutations such as R175H (Pitolli et al., 2019). These three 
mutants of p53 abolish an important function of p53, suppressing the formation of tumors 
in the cells of the body (Liu et al., 2010). Along with the loss of function of helping 
DNA-damaged cells, these mutants are more likely to gain new oncogenic activities such 
as increasing resistance to chemotherapy and increasing the resistance of cells to 
programmed cell death pathways and apoptosis (Liu et al., 2010). In particular, by 
analyzing the three most common mutations of p53 (R248W, R273H, and R175H), one 
study has shown that this loss of function due to these p53 mutants is directly tied to 
inactivating ataxia-telangiectasia mutated (ATM) function (Song et al., 2007). One of 
ATM’s functions is the regulation of cellular responses to DNA double-stranded break 
damage along with helping to control the rate of cells dividing or growing (Liu et al., 
2010; Xu, 2006). By inactivating ATM and its function, these p53 mutants induce genetic 
instability, a hallmark of cancer (Liu et al., 2010). Instead of acting as the gatekeeper of 
the cell cycle and programmed cell death, these mutants act to keep DNA-damaged cells 
alive and replicating. 
The function of p53 as a tumor suppressor is two-fold. First, p53 induces 
apoptosis in cells by way of programmed cell death in which mitochondrial physiology 
changes, cysteine protease activation, and DNA degradation lead to the death of a cell 
(Innocente et al., 1999). The second method is affecting the cell cycle to halt the 
replication of cells. Two targets in the cell cycle that p53 targets are cell cycle arrest at 
G1 by way of transcriptional downregulation of genes and the decrease of intracellular 
 
3 
levels of proteins such as Cyclin B1 to lead to cell cycle arrest at the G2/M transition 
(Innocente et al., 1999). The first target of cell cycle, arrest at G1, is completed by the 
accumulation of p21 by p53 when sensing cells in G1 are exposed to DNA-damaging 
agents (Innocente et al., 1999; Nam & van Deursen, 2014). P21 is responsible for the 
inactivation of CDKs (cyclin-dependent kinase) in order to halt the initiation of DNA 
synthesis, thereby halting the cell cycle at the G1/S checkpoint (Abukhdeir & Park, 2008; 
Innocente et al., 1999; Pitolli et al., 2019). The second target, the G2/M checkpoint, is 
necessary for stopping the cell from entering mitosis and replicating. In order to stop 
mitosis, p53 decreases the intracellular levels of cyclin B1 and reduces the activity of the 
cyclin B1 promoters (Nantajit et al., 2010). Cyclin B, a regulatory subunit of CDC2 
kinase, is a protein that, in the cell cycle, is necessary for mitotic initiation (Nantajit et al., 
2010). By lowering these levels, the cell cycle is halted at the G2/M checkpoint in order 
to stop the replication of DNA-damaged cells. In each of these cases, p53’s pathway to 
halt the cell cycle occurs by way of the dimerization partner, RB-like, E2F and multi-
vulval Class B Complex (DREAM) pathway (Engeland, 2018).  
The DREAM Pathway 
As seen in Figure 1, the DREAM complex is made up of MuvB, the core of the 
complex, along with LIN9, LIN37, LIN52, LIN54, and RBBP4 subunits (Fischer et al., 
2013). The core of DREAM is able to recruit E2F4/DP1 or E2F5/DP1 and RB-like 
proteins p130 or p107 in order to initiate repression or expression of genes (Fischer et al., 
2013). The DREAM core, MuvB, is also able to bind cell cycle genes homology region 
(CHR) domains based on the subunit LIN52 (Sadasivam & DeCaprio, 2013). By 
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phosphorylating the serine 28 (S28) residue of LIN52, DREAM is assembled and can 
bind the RB-like protein, p130, to the core of DREAM, MuvB (Sadasivam & DeCaprio, 
2013). The specific residue S28 was found to be the key residue in the formation of the 
DREAM complex due to studies that experimented with either replacing the serine with 
an alanine or using a knockout p130 RB-like protein (Guiley et al., 2015). These studies 
show that this residue and its phosphorylation are required for the formation of the 
DREAM complex and the repression/activation of genes via E2F or CHR domains. The 
DREAM protein complex binds to either E2F or CHR promoter sites in order to bind 
DNA via those domains to either halt or activate gene expression (Engeland, 2018). Each 
specific protein in the DREAM complex has a role in the binding of DNA for gene 







Figure 1: The P53-P21-DREAM-E2F/CHR Pathway for Repression and Activation of 
Genes. Indirect p53-dependent repression through DREAM. Induction of p21/CDKN1A by p53 
leads to hypophosphorylation of RB-like proteins p107 and p130. This hypophosphorylation 
facilitates the formation of the DREAM complex. This complex displaces the B-Myb-MuvB-
FOXM1 activating complex to repress gene expression. Overall, p53 indirectly downregulates 
previously activated genes through the DREAM pathway. This figure was adapted from 
(Engeland, 2018). 
 
DREAM Pathway: Repression 
Gene suppression occurs at quiescence (G0 and early G1), where the gene 
expression of cell-cycle-dependent genes is halted (Engeland, 2018). Genes are 
suppressed that are involved in the cell cycle, which include: CCNB1 (cyclin B1), 
CCNB2 (cyclin B2), KIF23, PLK4, BIRC5, CDC25C, and PLK1 (Engeland, 2018; 
Sadasivam & DeCaprio, 2013). This suppression is dictated by the association of RB-like 
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proteins p130 and p107 with the core, MuvB, and by the association with the E2F4-
5/DP1-2 (Fischer et al., 2013). These RB-like proteins are hypophosphorylated indirectly 
by p53 through the process of expression of p21 protein (Sadasivam & DeCaprio, 2013). 
P21, along with an inactivated CDKN1A protein that is responsible for regulation of 
cyclin-dependent kinase (CDK) complexes, acts as a checkpoint for cell cycle 
progression at G1 (Abukhdeir & Park, 2008; Choi et al., 2003). These 
hypophosphorylated RB-like proteins bind to the core of the DREAM complex, facilitate 
its formation, and lead to the repression of gene expression during quiescence and the 
arrest of the cell cycle. (Engeland, 2018).  
DREAM Pathway: Transactivation 
As shown in Figure 2, along with repressing gene expression during quiescence, 
DREAM is also responsible for activating gene expression that has peaks during G1/S 
and G2/M of the cell cycle. (Sadasivam & DeCaprio, 2013). This switch from repression 
to activation is facilitated by a loss of hypophosphorylation of the RB-like proteins so 
they cannot bind to the core of DREAM (Guiley et al., 2015). With the loss of this 
association, repression of the transcription of DNA is halted. Instead, this leads to an 
association of B-MYB or FOXM1 with the core of DREAM (Engeland, 2018). This core, 
MuvB, changes the complex’s structure and action (Engeland, 2018). With the protein 
composition changed from DREAM to B-MYB-MuvB (MMB), FOXM1-MMB, or 
FOXM1-MuvB based on the associations within the protein complex, this complex is 
converted from a repressor of gene expression to an activator of gene expression 
(Engeland, 2018). This transactivation of the DREAM complex requires the 
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phosphorylation of B-MYB by way of cyclin A-CDK2 (Sadasivam & DeCaprio, 2013). 
Without this phosphorylation by cyclin A-CDK2 a reduction in the expression of late cell 
cycle genes around the G2/M checkpoint is observed. (Sadasivam & DeCaprio, 2013). 
The peaks of activation of gene expression for DREAM are the G1/S checkpoint 
and the G2/M checkpoint in the cell cycle. Instead of binding the repressor E2Fs 
(E2F4/E2F5) and CHRs, DREAM in the form of MMB, FOXM1-MMB, or FOXM1-
MuvB binds to activator E2Fs (E2F1, E2F2, and E2F3) and CHRs for genes with peak 
expression at the G1/S transition (Sadasivam & DeCaprio, 2013). These genes are mostly 
responsible for DNA synthesis in the replication process of a cell (Sadasivam & 
DeCaprio, 2013). Similar to the G1/S checkpoint, the G2/M checkpoint is also important 
to gene expression in the cell cycle. At this point, genes that were repressed by DREAM 
under its association with repressor E2Fs and CHRs are now activated. These genes of 
the G2/M checkpoint include: CCNB1 (cyclin B1), CCNB2 (cyclin B2), CDK1, PLK1, 
and UBE2C (ubiquitin conjugating enzyme 2C) (Engeland, 2018; Sadasivam & 
DeCaprio, 2013). These genes, along with others that are activated, are vital to the start of 






Figure 2: Cell cycle control by DREAM. MuvB core is central to the binding and 
directing of key transcription factors during the various cell cycle phases. MuvB binds to 
p130-E2F4-DP in G0 to form DREAM and repress all cell cycle-dependent gene 
expression. LIN52’s phosphorylation is vital in the association between MuvB and p130-
E2F4. During S phase, B-Myb is recruited by MuvB and FOXM1 to the promoters of 
G2/M genes. This figure was adapted from (Sadasivam & DeCaprio, 2013). 
Balance of DREAM 
The balance between these two functions of DREAM, repression and activation of 
gene expression, can be influenced by p53 (Sadasivam & DeCaprio, 2013). Studies show 
that an increased activation of p53 in cells that are treated with DNA-damaging agents 
result in an increase in p130-DREAM and a decrease in the association of B-MYB, 
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which leads to increased repression of gene expression (Mannefeld et al., 2009; Quaas et 
al., 2012). This shift in function is due to p21. Because of the p53-dependent induction of 
p21, inhibition of cyclin A-CDK2 can lead to a reduced association between MuvB and 
either B-MYB or FOXM1 (Sadasivam & DeCaprio, 2013). Accordingly, with an 
inhibited cyclin A-CDK2, there is a shift in the balance leading to p130-DREAM and 
repression of gene expression. Overall, p53 indirectly causes the upregulation or 
downregulation of gene expression in each phase of the cell cycle by way of the 
formation of DREAM and B-MYB-MuvB-FOXM1 complexes to repress gene 
expression or activate gene expression, respectively.  
Effect of p53 Mutations 
Mutations to the TP53, as discussed before, have an impact on the p53-DREAM 
pathway. Due to p53’s role in the DREAM pathway, a mutation or mutations to the TP53 
gene can affect the repression pathway of DREAM and the activation pathway of B-
MYB-MuvB-FOXM1. If the mutation causes the p53 to be absent or disrupted, this will 
affect the regulation of cell cycle genes. Instead of regulating the oncoproteins involved 
in the expression of cell cycle genes in the p53-DREAM pathway in order to halt growth 
and replication of cells, mutations such as the “hotspot” mutations described earlier lead 
to phosphorylation of RB-like proteins, p107 and p130. This occurs because 
p21/CDKN1A was not induced by the p53 protein due to its mutation or mutations. 
Accordingly, instead of inhibiting kinases to cause a hypophosphorylation of these RB-
like proteins, they are phosphorylated. Due to this phosphorylation of the RB-like 
proteins, the DREAM complex is not formed to repress cell cycle genes, and the 
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activating complex, B-MYB-MuvB-FOXM1, stays active to keep the cell growing the 
replicating. With the cell cycle genes not repressed, this results in the accumulation of 
p53, a sign of aggressiveness in pituitary adenomas and pituitary carcinomas (De Sousa 
& McCormack, 2000). 
 
Pituitary Adenomas and Carcinomas 
 Of all intracranial tumors, human pituitary adenomas are the second most 
common. They usually arise from the secreting cells of the anterior pituitary gland (Zhou 
et al., 2015). Patients with pituitary adenomas may exhibit symptoms of endocrine 
dysfunction, which include hormone hypersecretion, infertility, decreased libido, and 
galactorrhea (Lake et al., 2013). They may also exhibit neurologic symptoms such as 
headache or visual changes (Lake et al., 2013).  
In the case of pituitary adenomas, there are both clinically functioning adenomas 
and clinically nonfunctioning adenomas. Clinically functional adenomas are adenomas 
that secrete hormones based on the cells of the pituitary that are affected. Accordingly, 
these clinically functioning adenomas include: growth hormone (GH) secreting, prolactin 
(PRL) secreting, adrenocorticotropin (ACTH) secreting, or thyrotropin (TSH) secreting 
(Zhou et al., 2015). The most common of these include the hypersecretion of prolactin 
causing hyperprolactinemia, growth hormone causing acromegaly, and 
adrenocorticotropin causing Cushing’s disease (Lake et al., 2013). In the case of PRL-
secreting pituitary adenomas, studies have shown that this hypersecretion is correlated 
with clinical symptoms such as irregular cycles and infertility along with neurological 
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symptoms, which include decreased verbal memory, nonverbal memory, and attention 
(Bala et al., 2016). In the case of GH-secreting pituitary adenomas, symptoms of 
acromegaly such as erectile dysfunction, swollen hands and feet, and vision disorders 
correlate with the hypersecretion of growth hormone. We will talk later about the 
specifics of ACTH-secreting pituitary adenomas. In rare instances, clinically functioning 
adenomas secreting gonadotropins, luteinizing hormone (LH) or follicle stimulating 
hormone (FSH), can lead to symptoms of excess gonadotropins (Zhou et al., 2015). 
These functional gonadotroph adenomas (FGA) secret one or both of the gonadotropins, 
FSH and LH (Cote et al., 2016). These FGAs can lead to symptoms of excess 
gonadotropins that include polycystic ovarian syndrome (PCOS), infertility, menstrual 
irregularities, ovarian hyperstimulation syndrome (OHSS), testicular hypertrophy, and 
sexual dysfunction (Cote et al., 2016). FGAs, with these symptoms, are often not detected 
due to the fact that other systemic diagnoses match the symptoms as well (Cote et al., 
2016). Since FGAs are uncommon, the initial diagnosis is usually incorrect, and the 
pituitary adenoma is not treated accordingly. With this is mind, FGAs are usually not 
identified until they become macroadenomas with symptoms of mass effect such as 
vision impairments and pain (Cote et al., 2016; Jaffe, 2006). Clinically nonfunctional 
pituitary adenomas do not secrete pituitary hormones. Therefore, blood panels to test for 
a hypersecretion of a pituitary hormone would not identify this class of pituitary 
adenomas. Of these clinically nonfunctioning pituitary adenomas, most are 
macroadenomas that come to clinical attention either due to mass effect of the 
macroadenoma that could lead to visual field defects and/or hypopituitarism (Jaffe, 
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2006). Larger nonfunctioning pituitary adenomas are also known to possibly become 
aggressive and/or persist after surgery (Ceccato et al., 2018). Some of these 
nonfunctioning pituitary adenomas are misidentified as nonfunctional gonadotrophs due 
to the fact that many of these nonfunctioning pituitary adenomas develop from 
gonadotroph cells of the pituitary (Cote et al., 2016).  
 The genetic background of pituitary adenomas is extremely diverse. Many 
identified cases still remain unclear as to the pathogenic mechanism (Tatsi & Stratakis, 
2019). However, germline genetic defects, tumor genetic defects, and somatic genetic 
changes such as copy number variation, epigenetic modifications, methylation changes, 
and miRNA abnormalities account for most pathogenic mechanisms for the formation of 
pituitary adenomas (Tatsi & Stratakis, 2019). It is also known that these pituitary 
adenomas are mostly monoclonal expansions, which is shown by X-chromosomal 
inactivation analysis (Lopes, 2010). These analyses were confirmed by independent 
analyses of GH-secreting pituitary adenomas, ACTH-secreting pituitary adenomas, and 
PRL-secreting pituitary adenomas (Zhou et al., 2015). Therefore, we can conclude that 
individual tumors are derived from single cells driven by a somatic gene mutation or 
multiple mutations (Zhou et al., 2015). Germline genetic defects account for a very small 
percentage of all patients, and these defects include: AIP (Familial Isolated Pituitary 
Adenoma Syndrome), MEN1 (Multiple Neoplasia type 1), PRKAR1A (Carney complex), 
GPR101 (X-linked Acrogigantism), and SDHx (“3 Ps Association including: 3 pituitary 
adenomas, pituitary adenomas with pheochromocytomas, and pituitary adenomas with 
paragangliomas) (Tatsi & Stratakis, 2019). Somatic mutations in genes such as TP53, 
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USP8, GNAS, USP48, and BRAF account for a larger percentage of the development of 
pituitary adenomas (Alexander et al., 1990; Tatsi & Stratakis, 2019; Zhou et al., 2015). 
  
Figure 3: Magnetic Resonance Imaging of Pituitary Macroadenoma. 
MRI image of a pituitary adenoma in the sellar region with a diameter of 18.74mm, 
which is classified as a macroadenoma. This figure was adapted from (Lake et al., 2013). 
 
Because of the large diversity of pituitary adenomas, identification of the pituitary 
adenoma and its treatment are sometimes challenging. Depending on whether or not the 
adenoma is clinically functioning, the endocrine symptoms of the adenoma would not 
show unless secreting a pituitary hormone. The size of the pituitary adenoma would 
determine if the adenoma is defined as a microadenoma or a macroadenoma. If the 
adenoma is smaller than 1cm in diameter, it is termed as a microadenoma. If larger than 
1cm in diameter, the adenoma is termed as a macroadenoma. As shown in Figure 3 
above, this pituitary adenoma is 18.74mm, an example of a pituitary macroadenoma. 
Along with determining if the pituitary adenoma is clinically functioning, it is also 
important to specify if the pituitary adenoma is aggressive or not. To this end, p53 has 
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been shown as a positive marker for invasive, aggressive pituitary adenomas 
(Alimohamadi et al., 2014; Schreiber et al., 1999). Depending on the variety of pituitary 
adenoma found, the course of treatment is different. In general, the three primary goals 
for pituitary adenomas are: reducing the hypersecretion of hormones and those associated 
clinical symptoms, reducing the size of the tumor to improve symptoms due to mass 
effect, and correcting possible hormone deficiencies (Lake et al., 2013). Below, Figure 4 
shows the course of identification and treatment for the variety of pituitary adenomas. 
 
Figure 4: Approach to the Evaluation and Treatment of Pituitary Adenomas.  
Based on the variety of pituitary adenoma, the course of action and management of the 
pituitary adenoma is shown. This figure was adapted from (Lake et al., 2013). 
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Pituitary adenomas have a diversity of identification, genetics, and treatment. 
However, the correlation between pituitary adenomas and p53 has not been well 
documented. P53 has been documented as a marker for aggressive pituitary adenomas 
(Tatsi & Stratakis, 2019). Also, excessive p53 immunoreactivity and/or a Ki67 index 
greater than 3% have also been a marker for “atypical” pituitary adenomas as defined by 
a 2004 World Health Organization classification (Borba et al., 2015; Miermeister et al., 
2015; Zada et al., 2011). Oliveira et al. studied a cohort of 148 patients, where 35% were 
nonfunctional and the remaining 65% were ACTH-, GH-, or PRL-secreting (Oliveira et 
al., 2002). They found the p53 protein to be positive in a only 2 of 148 pituitary adenoma 
samples, where both of these hypersecreted GH and PRL (Oliveira et al., 2002). Out of 
all the studies performed on pituitary adenomas, there has been only one study by 
Kawashima et al., which found a TP53 somatic mutation in an atypical corticotroph 
adenoma (Kawashima et al., 2009). 
Human pituitary carcinomas are much more rare than pituitary adenomas, and 
they are only usually diagnosed due to the pituitary tumor being noncontiguous with the 
sella turcica region and/or the pituitary tumor metastasized to distant sites from the 
pituitary (Heaney, 2011; Ragel & Couldwell, 2004). The metastasis required for the 
definition of a pituitary carcinoma is either a craniospinal dissemination or systemic 
metastasis (Lopes, 2010). These tumors often show a proclivity for systemic metastasis 
instead of craniospinal dissemination, with a reported frequency of 47% systemic 
metastases, 40% craniospinal dissemination, and 13% exhibiting both of these (Heaney, 
2011; Pernicone et al., 1997). Being so rare, they only account for approximately 0.1% of 
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all pituitary tumors identified (Heaney, 2011). The process of identifying a pituitary 
carcinoma usually starts with the initial identification of a clinically functioning, invasive 
macroadenoma (Ragel & Couldwell, 2004). Because of this initial identification, most 
cases of reported pituitary carcinomas are hormonally active tumors with hormone 
secretion that is indistinguishable from pituitary adenomas (Lopes, 2010). The most 
common of these are ACTH- and PRL-secreting tumors, and the latency period between 
the initial identification of an aggressive pituitary macroadenoma and the final diagnosis 
of a pituitary carcinoma can last 9.5 years for ACTH-secreting carcinomas and 4.7 years 
for PRL-secreting carcinomas (Ragel & Couldwell, 2004). Overall, this latency period 
has wide range of a few months to 18 years (Ragel & Couldwell, 2004). This wide range 
is due to the metastasis of the pituitary tumor to a distant site from the sella turcica that is 
required for the diagnosis of a pituitary carcinoma. 
The plan of treatment for these carcinomas is diverse, and treatments and 
therapies are not well documented. The options for treatment of pituitary carcinomas is 
similar to that of aggressive pituitary macroadenomas (Kaltsas et al., 2005). These 
options include: Surgery (usually by way of the transsphenoidal route), radiation therapy, 
adjunct medical therapies, and chemotherapy. First, surgeries of pituitary carcinomas are 
rarely curative due to the pituitary carcinomas being locally invasive into the sellar floor 
and/or the cavernous sinus, but they aid in the diagnostic effort for the patient (Heaney, 
2011; Kaltsas et al., 2005). This method is effective at providing immediate relief of mass 
effect symptoms such as compression and vision impairment (Heaney, 2011). Usually 
second, radiation therapy is administered to prevent the regrowth of the surgically 
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removed tumor and to slow the growth of metastatic deposits (Heaney, 2011). Two 
methods of delivery of radiation therapy include stereotactic radiosurgery (SRS) and 
fractionized radiation therapy (Heaney, 2011). Both of these methods can be adapted by 
the various forms of delivery such as -knife, linear accelerator, cyberknife, and proton 
beam therapy to increase the efficacy of the treatment. However, there is no data to 
suggest that radiotherapy improves the prognosis of the patient with a pituitary carcinoma 
even though it is shown to prevent additional tumor growth and possibly cause a partial 
remission of the tumor (Kaltsas et al., 2005). Third, adjunct medical therapies such as 
dopamine agonists and somatostatin analogs can be used to treat PRL-secreting pituitary 
carcinomas and GH-secreting pituitary carcinomas, respectively (Heaney, 2011; Kaltsas 
et al., 2005). The dopamine agonists, bromocriptine, quinagolide, and cabergoline, help 
to achieve biochemical control over the pituitary carcinoma but may be limited by the 
orthostatic side effects (Kaltsas et al., 2005). The patient may develop a resistance to 
dopamine or escape the treatment altogether (Kaltsas et al., 2005). The somatostatin 
analogs, octreotide and lanreotide, help to biochemically control the hypersecretion of 
growth hormone (Kaltsas et al., 2005), However, in each of these therapies, the outcomes 
are varied with not much improvement shown in either of these treatment options. Third, 
chemotherapy is a broad plan of treatment. The most commonly used drugs to treat 
pituitary carcinomas are cyclohexyl-chloroethyl-nitrosourea (CCNU) along with 5-
fluorouracil (5FU) and temozolomide (TMZ) (Garmes et al., 2017; Heaney, 2011). TMZ 
has become the most frequently prescribed chemotherapy for pituitary carcinomas due to 
its documented increase in longevity in the patients treated (Santos-Pinheiro et al., 2019). 
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Even with all of these well-documented plans of treatment for pituitary carcinomas, there 
is still no curative treatment. Treatments such as surgery that are used in combination 
with biochemical controls like dopamine agonists and chemotherapies like TMZ improve 
the outcomes for patients and are correlated with an increase in longevity for the patient. 
Due to the rarity of pituitary carcinomas and lack of documented cases, the 
correlation between pituitary carcinomas and p53 is not largely discussed or reported. 
Tanizaki et al. analyzed a cohort of patients with either pituitary adenomas or pituitary 
carcinomas (Tanizaki et al., 2007). By way of PCR amplification and sequencing of 
exons 5-8 of p53, they found that 3 carcinomas had at least a 20% expression of p53 
(Tanizaki et al., 2007) Of these 3 carcinomas, 1 carcinoma had a 60% overexpression of 
p53, which had a hotspot mutation at codon 248 (Tanizaki et al., 2007). Another of these 
3 pituitary carcinomas had a 90% overexpression of p53 with a hotspot mutation in the 
135 codon (Tanizaki et al., 2007). These results conclude that p53 mutations are found in 
pituitary carcinomas.  
 
Corticotropic Tumors 
 Corticotropic tumors are pituitary adenomas or pituitary carcinomas that are either 
clinically functioning and clinically nonfunctioning (silent). If clinically functioning, 
these secrete adrenocorticotropin (ACTH). Corticotropic adenomas make up 
approximately 10-15% of all pituitary adenomas (Xiong & Ge, 2016). Of these 
corticotropic adenomas, the majority are microadenomas and, therefore, do not cause 
symptoms of mass effect like macroadenomas (Mathioudakis et al., 2012). Because of 
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these microadenomas not having the symptoms of mass effect, corticotropic tumors are 
usually identified due to the hypersecretion of ACTH or the hypersecretion of 
downstream hormones of ACTH such as cortisol in the adrenal gland (Mathioudakis et 
al., 2012). However, if the patient is suffering from a clinically functioning corticotropic 
macroadenoma, the classical symptoms of mass effect would also come into play in the 
identification of the corticotropic adenoma (Mathioudakis et al., 2012). 
 As mentioned earlier on the origins and genetic background of pituitary 
adenomas and pituitary carcinomas, the origins of ACTH-secreting pituitary tumors are 
found to be monoclonal in nature (Biller et al., 1992). By the same method of X-linked 
restriction fragment length polymorphisms, Biller et al. found that the tumor tissue from 
the 10 women with ACTH-secreting pituitary microadenomas demonstrated a 
monoclonal pattern (Biller et al., 1992). From this starting point, we can move forward 
with the idea that distinct genetic changes are the most important part in the 
tumorigenesis within the pituitary gland (Xiong & Ge, 2016). Along with the fact 
germline mutation account for a tiny percentage of all pituitary tumors, studies suggest 
that corticotropic tumors are derived from single cells driven by a somatic mutation or 
mutations (Biller et al., 1992; Zhou et al., 2015). In 35-62% of Cushing’s disease-causing 
corticotropic adenomas, the deubiquitinase gene, USP8, was found to have somatic 
mutations (Perez-Rivas & Reincke, 2016). P27, a cell cycle regulator at the G1/S 
checkpoint, was also found to be underexpressed in pituitary adenomas as compared to a 
normal pituitary gland (Bi et al., 2017; Seltzer et al., 2015). Unfortunately, the genetic 
factors involved in corticotropic tumorigenesis are largely unknown (Uzilov et al., 2017). 
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Cushing’s disease (CD) is a severe and potentially fatal disease caused by this 
hypersecretion of ACTH in the anterior pituitary gland (Xiong & Ge, 2016). This results 
in symptoms, which include: central obesity, moon face, hirsutism, glucose intolerance, 
osteoporosis, metabolic complications, neuromuscular weakness, and mood changes 
(Uzilov et al., 2017; Xiong & Ge, 2016). 
Due to this excess of glucocorticoids produced in the adrenal glands in response 
to the increase in ACTH secretion by the corticotropic tumor, corticotroph cells that 
surround the tumor undergo Crooke’s hyaline change (Radovanovic et al., 2020). This 
specific hyaline change pertains to these cells accumulating cytokeratin filaments in the 
cytoplasm as a feedback inhibition response to suppress the production of ACTH (George 
et al., 2003; Radovanovic et al., 2020). In the rare cases of Crooke’s adenomas, the 
ACTH-producing cells of the corticotropic tumor proceed through these hyaline changes 
(Di Ieva et al., 2015; Radovanovic et al., 2020). Even though these cells should suppress 
the production of ACTH, Crooke’s adenomas are instead known for being invasive and 





 Studies have yet to conclude if there is a correlation between corticotropic tumors 
and mutations in the TP53 gene or in the p53 protein. In addition, these studies have 
either faltered due to their small sample sizes or due to the lack of ongoing clinical 
follow-ups with the patients in these studies. Even though some studies have documented 
few cases of mutations found the TP53 gene with corticotropic tumor patients, the 
general consensus is that more patients are needed, and more studies need to be 
completed to conclude about this correlation. 
 This thesis seeks to describe a cohort of patients with functional corticotropic 
tumors and patients with silent (nonfunctioning) corticotropic tumors. In this cohort of 
patients, this thesis strives to find gene mutations in this cohort to find a correlation 
between TP53 gene mutations that would affect the functionality of the p53 protein and 











Cohort Selection and Preparation of Samples 
 This study was reviewed and approved by the institutional review boards (IRBs) 
for human subjects of the Brigham and Women’s Hospital. Informed and written consent 
was received from all patients in the cohort for this study. Initial diagnosis of all patients 
was determined before entrance to the study to determine whether each patient met the 
clinical requirements for the study. Patient data describing their age, sex, and ethnicity 
was received from each of the 36 patients described in the cohort. Each of these patients 
was classified as either clinically functioning or silent based on the secretion levels of 
ACTH, cortisol, or a pathology report showing ACTH positive staining. For each of the 
patients, tumor size was identified to determine if the patients had a microadenoma 
(<1cm) or a macroadenoma (>1cm). In this study, we focused on the corticotropic 
adenomas, whether functioning or nonfunctioning. For the cases where functioning 
corticotropic adenomas were found, these were classified as patients with Cushing’s 
disease based on elevated serum levels of ACTH and cortisol. DNA was extracted from 
tumor tissue samples from each patient in the cohort. That sample DNA for each patient 
was, then, paired with DNA from the subject via either blood or saliva, if available, to 
ensure the validity of the results using the standard procedures (Qiagen, Valencia, CA). 
The DNA from the sample and the paired DNA, if available, were quantified using the  
PicoGreen system (Invitrogen) (Bi et al., 2017). For each of the patients in the cohort, the 
medical history was assessed to find familial disorders regarding corticotropic adenomas.  
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Whole-Exome Sequencing (WES) 
 In order to analyze these samples from the tumors of the patients in the cohort 
studied, this study used whole-exome sequencing (WES). With the use of whole-exome 
sequencing, this study was able to identify somatic mutations with regard to the pituitary 
adenomas samples (Bi et al., 2017). Samples were submitted to the Broad Institute, and 
DNA extraction was performed. This extracted DNA was submitted for whole-exome 
sequencing. 38 samples of pituitary adenomas underwent whole-exome sequencing with 
the DNA matched from the patient, if available, via either blood, saliva, or germline 
DNA. In order to complete the WES, each of the samples was sonicated to 250 base pair 
fragments, which was selected with Agencourt AMPure XP beads, and these fragments 
were ligated to specific barcode adaptors (Illumina TruSeq; Illumina Inc., San Diego, 
CA) for a multiplexed analysis (Bi et al., 2017). With the use of Agilent SureSelect 
hybrid capture kit (Whole Exome_v4; Agilent Technologies, Santa Clara, CA), exome 
hybrid capture was achieved (Bi et al., 2017). Once exome hybrid capture was 
completed, the samples were sequenced via a HiSeq 2500 System (Illumina Inc., San 
Diego, CA) (Bi et al., 2017). 
 Afterwards, the sequence data found was aligned to the hg19 (b37) reference 
sequence. This aligning process was completed using the Burrows-Wheeler Aligner (Bi 
et al., 2017). Using SAMtools and Picard, these readouts were, then, sorted, duplicate-
marked, and indexed (Bi et al., 2017). After assigning bias in base quality due to flowcell, 
lane, dinucleotide context, and machine cycle, these were analyzed and recalibrated for 
quality control. The use of Genome Analysis Toolkit (GATK) found local realignment 
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around insertions and deletions (Bi et al., 2017). To ensure quality control in the samples 
that were sequenced and the accuracy of the tumor-normal pairs, all of the paired samples 
of the pituitary tumor samples were tested (Bi et al., 2017). 
 
Somatic Mutation Verification 
 Each of the TP53 gene mutations found in whole-exome sequencing to form p53 
variants are predicted to be pathogenic or likely pathogenic by several different databases 
and software. These databases and software include: ClinVar, COSMIC, GENOME, 


















Cohort Descriptive Analysis 
During this study, 38 samples from 36 patients were obtained, and whole-exome 
sequencing was completed on the tumor samples and, if available, the paired DNA. There 
were two patients that had two separate samples used in the study. For the first patient 
(samples 24 and 25), the samples were from an initial adenoma in 2012 and a recurrent 
adenoma in 2018. For the second patient (samples 28 and 29), the samples were from an 
initial adenoma in 2011 and a recurrent adenoma in 2015. Tumor samples from the 
cohort were from both microadenomas and macroadenoma depending on the size 
determined for each of the patients. From the 38 samples of tumors from 36 different 
patients, there were three overall classifications for the patients. Out of these 36 patients, 
56% (20/36) were functional corticotrophs, 39% (14/36) were silent (nonfunctional) 
corticotrophs, and 5% (2/36) were classified as unknown. These two unknown tumors 
were classified as that due to the fact that these patients suffered a pituitary apoplexy. 
Due to these apoplexies, the proper workup was not possible before the surgery, and it 
was not possible to ascertain whether or not the patient had a functional or silent 
corticotropic adenoma. In each of the samples classified as functional corticotrophs, these 
samples were also classified as Cushing’s disease due to the hypersecretion of ACTH in 
each of the cases. For the 20 patients with a functional corticotropic adenoma, the age 
ranged from the youngest at 20 years of age to the oldest at 73 years of age. The median 
of the range of ages of the patients with functional corticotrophs was 53. The age of these 
patients had a mean age of 50.8 with a standard deviation from the mean of 15.7. For the 
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14 patients with silent corticotrophs, the age of the patients ranged from 22 years of age 
to 79 years of age. The median of age for the patients with silent corticotrophs was 50, 
and the mean of the ages was 54.4 with a standard deviation from the mean of 17.1. The 
sex of the patients with functional corticotrophs was predominantly female at 80% 
(16/20), and the male sex accounted for 20% (4/20). The sex of the patients with silent 
corticotrophs was also predominantly female at 64% (9/14), and males accounted for 
36% (5/14). The ethnicities of the patients varied between African American, Hispanic, 
Arabic/Asian, South Asian, and Caucasian. The breakdown of the frequency of each 
ethnicity in the study includes: 75% (27/36) Caucasian, 16% (6/36) Hispanic, 3% (1/36) 
African American, 3% (1/36) South Asian, and 3% (1/36) Arabic/Asian.  The tumors of 
each of these patients in the cohort were identified as either micro or macro depending on 
whether the diameter of the pituitary adenoma was larger or smaller than 1cm. Out of the 
36 patients in the cohort, 75% (27/36) of the patients were identified as having a 
macroadenoma, and 25% (9/36) were identified as having microadenomas. Out of the 27 
patients that were identified as having a macroadenoma, 74% (20/27) were found to have 
at least one compressive symptom of mass effect due to the macroadenoma such as 
headaches (20/36) or vision blurring (18/36).  
 
Whole-Exome Sequencing Analysis 
 Using the WES methodology, somatic mutations and germline mutations were 
accounted, if found, in each of the 38 samples that were sequenced. A variety of somatic 
mutations were found via WES, and these are categorized in Table 1. Other than three 
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cases where a mutation in TP53 was found, somatic mutations in USP48, USP8, DAXX, 
CTNNA2, HDAC4, IKZF1, SMAD7, PDE11A, CDC27, LARP1, CDKN2A, ATRX, and 
SMAD3 were also found in the cohort. Of these 38 tumor samples from the patient 
cohort, one was found to have a somatic mutation in the USP48 gene, nine were found to 
have a somatic mutation in the USP8 gene, four had a somatic mutation in the DAXX 
gene, two had a somatic mutation in the CTNNA2 gene, two had a somatic mutation in 
the HDAC4 gene, one had a somatic mutation in the IKZF1 gene, three had a somatic 
mutation in the SMAD7 gene, two had a somatic mutation in the PDE11A gene, two had a 
somatic mutation in the CDC27 gene, one had a somatic mutation in the LARP1 gene, 
one had a somatic mutation in the CDKN2A gene, one had a somatic mutation in the 
ATRX gene, and one had a somatic mutation in the SMAD3 gene. 
 In the three samples (29, 30, and 36) where mutations in the TP53 gene were 
found, different somatic mutations of the TP53 gene were found. Of these three samples, 
all three were nonfunctional (silent) macroadenomas.  
In sample 29, two separate mutations in TP53 were found via whole-exome 
sequencing. The first mutation was a somatic missense mutation in codon 743, where 
glycine was replaced by alanine to produce the variant p53 protein, R248Q. The R248Q 
is a previously described, “hotspot,” mutation for TP53 at exon 7, and it is known to be 
nonfunctional and damaging. The ClinVar database reported this TP53 mutation as 
pathogenic (ID:12356) with 52 reports of this mutation being pathogenic or being likely 
pathogenic, and COSMIC has also reported this TP53 mutation as pathogenic with a 
FATHMM predictive score of 0.98 (ID:10662). According to studies and the ClinVar 
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database, this common p53 variant, R248Q, is found in a diverse range of cancers from a 
small cell lung carcinoma, a melanoma of the skin, and sarcomas to Li Fraumeni familial 
cancers of the breast and colon (Chang et al., 2016; Manoharan et al., 2019, 2020; 
Richards et al., 2015). The second mutation found in sample 29 was a somatic missense 
mutation in codon 523, where cysteine was replaced with threonine to produce the variant 
p53 protein, R175C. The R175C mutation is found at exon 5, but is not a “hotspot” 
mutation. ClinVar reported this somatic mutation to be of uncertain significance due to 4 
out of the 28 reports on the mutation having an uncertain significance interpretation 
(ID:245851). COSMIC’s report conflicts with the findings of ClinVar. COSMIC reported 
this mutation to be pathogenic with a FATHMM predictive score of 0.97 (ID:43680). 
ClinVar and a study by Chang et al. also show the common p53 variant, R175C, to be 
present in cancers other than pituitary adenomas throughout the body such as a pancreatic 
adenocarcinomas, a melanoma of the skin, a lung adenocarcinoma, and an 
adenocarcinoma of the stomach (Chang et al., 2016). Since this patient has two mutations 
in the TP53 gene, this sample is classified as having a composite mutation in TP53 gene 
(Gorelick et al., 2020). This composite mutation would result in a gain of function to the 
p53 protein that would protect growth and replication in the affected cells along with its 
loss in function as a tumor suppressor (Gorelick et al., 2020). Overall, the expected effect 
of this composite mutation would be the halt of formation of the DREAM complex to 
halt repression of cell cycle genes and the continual activation of the B-MYB-MuvB-
FOXM1 complex to express cell cycle genes along with protection of oncoproteins such 
as B-MYB and FOXM1. In addition, a somatic mutation in the DAXX gene was found in 
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this sample. Due to DAXX’s role in encoding a chaperone for the histone 3.3 variant, 
mutations in the DAXX gene are commonly found in the formation of cancers such as 
pancreatic neuroendocrine tumors, ovarian cancer, prostate cancer, and gastric cancer 
(Mahmud & Liao, 2019; Wasylishen et al., 2020). This concomitant mutation functions 
to halt DNA repair mechanisms and facilitate the formation of tumors. In 1998, when the 
patient presented with headaches, an MRI showed a macroadenoma, and the patient 
underwent trans-nasal transsphenoidal surgery. In 2011, during an MRI of a development 
of a left-sided temporal hemianopia, a recurrent lobulated mass was also seen within the 
sellar and suprasellar region with mass effect symptoms and evidence of cavernous sinus 
invasion. A second resection was completed in 2011, and pathology showed a 1.6cm 
pituitary adenoma with evidence of Crooke’s adenoma, weak-positive ACTH staining, 
and a proliferative index of less than 2%. After surgery, the patient was treated with 
gamma knife radiosurgery for residual disease. Recurrence was observed in 2015 after an 
MRI revealed a recurrence at the level of the tuberculum, which contacted the optic 
apparatus and was involved in the left cavernous sinus. A third resection was completed 
in 2015 to remove the intrasellar invasive pituitary adenoma. Pathology of this resection 
reported positive ACTH staining with a proliferative index of 2.81%. Upon consultation, 
the patient was treated with TMZ and capecitabine. In 2016, an MRI revealed a decreased 
size in the parasellar mass since 2015 in all compartments with evidence of cystic 
degeneration versus necrosis in the middle cranial fossa component. The patient is 
undergoing radiation therapy with proton SRS at Massachusetts General Hospital.  
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In sample 30, one mutation in TP53 was found via WES. This mutation was a 
somatic mutation at codon 641, where histidine was replaced with arginine, producing the 
variant H214R p53 protein. This variant is also a classified as a temperature-sensitive 
variant due to the fact that a mutant conformation of the protein is achieved at 
physiological temperatures, while a wild-type conformation is achieved at lower 
temperatures (Shiraishi et al., 2004). According to ClinVar, this somatic mutation is 
likely pathogenic due to 14 out of the 15 reports on the mutation interpreting as likely 
pathogenic (ID:376615). COSMIC reports that this mutation is pathogenic with a 
FATHMM predictive score of 0.99 (ID:43687). The p53 variant, H214R, has been shown 
to be in other cancers of the body including: A squamous cell lung carcinoma, carcinoma 
of the esophagus, hepatocellular carcinoma, and a transitional cell carcinoma of the 
bladder (Chang et al., 2016). Overall, this variant, H214R, has the expectation of the loss 
of function as a tumor suppressor and the protection of oncoproteins in the cell cycle such 
as FOXM1 and B-MYB as discussed earlier. This patient (sample 30) was treated after 
initial diagnosis in 2010 with emergent debulking and radiation therapy. Upon recurrence 
in 2014, tumor resection was completed along with a repeat radiation therapy with proton 
SRS therapy. In this recurrence, the pathology found a 1.2cm pituitary adenoma with 
positive staining for ACTH, a very strong staining for p53, and a proliferative index of 
>5%. In 2016, MRI showed growth in the left sella, and the patient underwent resection 
and radiation therapy. Pathology found a 1.1cm pituitary adenoma with positive staining 
for ACTH and p53 along with a proliferative index of 15%, and the patient was treated 
with proton SRS. In 2018, with MRI findings consistent with possible recurrence, the 
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patient was treated with TMZ.  These findings met WHO criteria for an atypical pituitary 
adenoma. 
In sample 36, a mutation was found affecting the splice donor site in intron 9, 
which causes an inclusion of intron 9 between exon 9 and exon 10. The splice donor 
mutation, c.993+1G>A, has the expectation of disrupting the RNA product, which would 
lead to an absent or disrupted TP53 gene product. According to ClinVar, this mutation is 
found to be pathogenic based on only three reports on the mutation (ID:52861). COSMIC 
also reports that this mutation is pathogenic with a FATHMM predictive score of 0.99 
(ID:45304). According to a study by Lee et al., this mutation found in TP53 in a pituitary 
adenoma is also found in non-small cell lung cancer (Lee et al., 2009). Due to this 
specific mutation causing a disrupted TP53 gene product, the p53 protein would be 
expected to lose its function in suppressing the formation of tumors by regulation of the 
p53-DREAM pathway and in repairing DNA damage via proteins such as ATM. In 
addition to the TP53 somatic mutation, a somatic mutation in the ATRX gene was found 
in this sample. According to a study by Pinto et al., concomitant mutations of TP53 and 
ATRX result in additional genetic abnormalities that include structural variations and 
frequent background mutations (Pinto et al., 2015). This concomitant mutation is 
consistent with aggressiveness in the growth of tumors (Pinto et al., 2015). Upon initial 
diagnosis in 2002 of a pituitary macroadenoma, this patient was treated by surgery for 
resection of pituitary macroadenoma. Upon the first recurrence in 2006, surgery for 
resection was completed, and, subsequently, the patient reported panhypopituitarism. 
Following diagnosis of panhypopituitarism, the patient was put on replacement therapy 
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with desmopressin (DDVAP), levothyroxine, estrogen, and progesterone. The patient was 
treated with gamma knife radiation in 2010. But, the patient suffered another recurrence 
in 2012, and the patient underwent a third resection. The pathology after this resection 
revealed that the tumor had positive ACTH staining and a proliferative index of 4-5%. In 
2014, the patient an elevated 24-hour urine cortisol and an elevated level of ACTH. 
Following a fourth resection with proton beam, pathology reported a 3.0cm pituitary 
adenoma with positive staining for ACTH/p53 and a proliferative index of 5.95%. Based 
on the positive staining of ACTH, the high proliferative rate, and cytologic atypia, it was 
classified as an atypical pituitary adenoma. In 2016, MRI showed an invasive, enlarging 
tumor, and the patient underwent a fifth resection. Pathology revealed that the adenoma 
had positive staining for ACTH and a proliferative index of 5%. The following year, the 
patient was treated with TMZ. During the TMZ treatment, the patient completed a 
craniotomy and a sixth resection after syncopal episodes. In 2018, low cortisol levels 
were observed in the patient. At the end of 2018, an MRI revealed progression on the 

















Table 1: Somatic Gene Mutations of Cohort Samples. 
Each tumor sample (1-38) is classified by functionality of the tumor. For each tumor 
sample, the type of paired DNA, if available, is shown. For each of the samples, the 






Pairing Somatic Gene Mutation 
1 Functional Yes Saliva USP48 (F299V) 
2 Functional Yes Saliva USP8 (P614R) 
3 Functional Yes Saliva USP8 
4 Functional Yes Saliva USP8 (P720Q) 
5 Functional Yes DNA DAXX/CTNNA2 
6 Functional Yes None Ø 
7 Functional Yes Saliva USP8 (S718P) 
8 Functional Yes Saliva Ø 
9 Functional Yes None USP8 (S718_T723del) 
10 Functional Yes Blood HDAC4/CTNNA2 
11 Functional Yes Blood Ø 
12 Functional Yes None USP8 (p.611_612del) 
13 Functional Yes Saliva Ø 
14 Functional Yes Saliva IKZF1 
15 Functional Yes Blood USP8 (P720R) 
16 Functional Yes None Ø 
17 Functional Yes None Ø 
18 Functional Yes None USP8 (p.611_612del) 
19 Functional Yes Blood USP8 (p.611_612del) 
20 Functional Yes None Ø 
21 Silent No None Ø 
22 Silent No None Ø 
23 Silent No Saliva Ø 
241 Silent No DNA SMAD7 
251 Silent No DNA SMAD7/PDE11A 
                   
26 Silent No None HDAC1 
               




Table 1 continued: Somatic Gene Mutations of Cohort Samples. 
Each tumor sample (1-38) is classified by functionality of the tumor. For each tumor 
sample, the type of paired DNA, if available, is shown. For each of the samples, the 
somatic gene mutations found by WES is shown.  






Pairing Somatic Gene Mutation 
282 Silent No Saliva DAXX/CDC27 




30 Silent No Saliva 
CDKN2A/TP53 
c.641A>G:p.H214R 
31 Silent No Blood DAXX/SMAD7 
32 Silent No Blood PDE11A 
33 Silent No None  Ø 
34 Silent No Saliva  Ø 
35 Silent No Blood  Ø 
36 Silent No Blood 
ATRX/P53 (splicing) exon 9 
c876+1G>A 
37 Unknown No Blood  Ø 
38 Unknown No Saliva 
















 The correlation between mutations in the p53 protein and the formation of various 
forms of pituitary adenomas has been evaluated in four studies (Guo et al., 2018; 
Kawashima et al., 2009; Tanizaki et al., 2007; Thapar et al., 1996). However, few studies 
have been able to show a correlation between mutations in the TP53 gene that produce a 
variant p53 protein and, specifically, corticotropic adenomas. The purpose of this study 
was to analyze this cohort by finding mutations in the TP53 gene. By so doing, a 
correlation between TP53 and the formation of corticotropic tumors, which has not been 
well-documented, can be found. The key findings from this study were the four TP53 
somatic mutations found in three samples analyzed by whole-exome sequencing out of 
the 38 samples from 36 patients in the study.  
 The first study completed by Guo et al. studied at 55-year-old with a ACTH-
secreting pituitary adenoma (Guo et al., 2018). Using immunohistochemistry, they found 
that the pituitary adenoma was positive for the expression of ACTH and p53 (Guo et al., 
2018). After coming to the conclusion that the pituitary adenoma was a pituitary 
carcinoma due to postoperative histopathologic examination, they found three somatic 
mutations in the genes ATRX, PTEN, and TP53 (Guo et al., 2018). Although this study 
found what they referred to as an uncommon p53 mutation along with two other 
mutations, this study came to no conclusion about the correlation between the TP53 
mutation and the corticotropic carcinoma studied, and the authors stated that further 
studies of a larger cohort must be completed to clarify the pathogenesis of pituitary 
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carcinomas. However, the rarity of the TP53 gene mutation was such that there was no 
definitive correlation between the formation of that tumor and the TP53 mutation. 
 In a study by Tanizaki et al., eight pituitary adenomas and six pituitary 
carcinomas were analyzed by immunohistochemistry and DNA sequencing from exon 5 
to exon 8 for genetic mutations (Tanizaki et al., 2007). Although all adenomas that were 
studied found no p53 mutations and only 15% of the cells had p53 expression, in three 
out of the six carcinomas studied, an elevated p53 expression of greater than 20% was 
found (Tanizaki et al., 2007). One of these three carcinomas had a 60% overexpression of 
p53 with a “hotspot” mutation at codon 248, and another of these three carcinomas had a 
90% overexpression of p53 at codon 135 (Tanizaki et al., 2007). Even though this study 
found p53 mutations in the pituitary carcinomas, no correlation between the 
tumorigenesis and p53 mutations was found. Although this study found no connection 
between the pituitary adenomas and p53, they did find primary pituitary carcinomas with 
TP53 mutations at codons 248 and 135. In comparison with this study, both studies found 
a TP53 mutation at codon 248 in pituitary tumors, but no correlation was drawn due to 
the small sample size of the cohort. 
 The study completed by Thapar et al. studied 70 pituitary adenomas 
(somatotrophs, lactotrophs, corticotrophs, and silent) and 7 primary pituitary carcinomas 
to evaluate their expression of the TP53 gene product (Thapar et al., 1996). Of these 77 
tumors studied, they found that 12 tumors that were identified as either invasive pituitary 
adenomas or primary pituitary carcinomas. These tumors also had conclusive nuclear 
immunopositivity for p53 expression (Thapar et al., 1996). Although no clear conclusion 
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was drawn between the increased expression of p53 and the tumorigenesis of these 
tumors, the study did find that the high levels of p53 expression were associated with the 
invasiveness of the pituitary adenomas and primary pituitary carcinomas (Thapar et al., 
1996). Unlike our small cohort, the large sample of tumors studied and the percentage 
(15%) of these tumors that had conclusive nuclear immunopositivity for p53 show a clear 
association between invasive pituitary adenomas/primary pituitary carcinomas and p53. 
 Most importantly, the study by Kawashima et al. examined the case of a 63-year-
old woman with the clinical features of Cushing’s disease caused by an atypical 
corticotropic adenoma (Kawashima et al., 2009). After sequencing the TP53 gene from 
exon 5 to exon 8 in the DNA of the tumor by way of direct sequencing using a 
polymerase chain reaction (PCR), a homozygous missense mutation at codon 145 was 
found to produce the L145R p53 protein variant, which was reported to be nonfunctional 
(Kawashima et al., 2009). According to ClinVar, this particular variant is of uncertain 
significance with only two reports of this variant (ID:418517). COSMIC reports 
conflicting data with ClinVar. According to COSMIC, the L145R p53 protein variant is 
pathogenic with a FATHMM predictive score of 1.00. No conclusion as to the correlation 
between this TP53 somatic mutation and the tumorigenesis of the corticotropic adenoma 
in the patient was drawn due to the fact that this study was the first study to find a TP53 
mutation in an atypical corticotropic adenoma. In comparison with this study, different 
mutations were found in our cohort, and, in our cohort, there were three separate samples 





 Based on the results from this study, I have two possibilities for future studies to 
uncover the pathogenesis of the formation of corticotropic adenomas. The first possibility 
is to obtain a larger sample size of patients with corticotropic adenomas. The second 
possibility is to look at downstream proteins of the p53-DREAM pathway of cell cycle 
control. 
 This first possibility to increase the sample size of the cohort of patients would 
only be achievable in a large longitudinal study covering multiple cities and countries. 
Due to most studies covering either a small sample or a few case studies, no conclusion 
has been drawn between TP53 gene mutations and the tumorigenesis of the corticotropic 
adenomas. However, with enough samples across a large variation of location, ages, 
ethnicities, and sex, a definitive conclusion as to the connection between p53 and the 
tumorigenesis of corticotropic adenomas might be possible. I realize that this possibility 
would be hard to achieve, but I believe that cooperation between research institutions 
across the country would serve as a strong starting point.  
 The second possibility, which is to look at the downstream proteins of the p53-
DREAM pathway of cell cycle control, is a viable option for future studies due to the 
numerous studies such as Herman et al. and Lübke et al., which found zero p53 
mutations (Herman et al., 1993; Lubke et al., 1995). As discussed in the introduction, the 
p53-DREAM pathway is how the p53 protein acts as a tumor suppressor to halt 
tumorigenesis. In the p53-DREAM pathway, there is a specific target, the p21 protein. 
The p21 protein encoded by the CDKN1A gene is important to the control of the 
 
39 
repression or expression of cell cycle genes (Engeland, 2018). P53 acts to indirectly 
cause the formation of the DREAM complex by way of the p21 protein. P21 is also a 
universal inhibitor of cyclin-dependent kinases (CDKs) and acts as a cell cycle blocker 
and growth inhibitor in cells (Neto et al., 2005). By using its function as an inhibitor of 
CDKs, p21 causes a hypophosphorylation of RB-like proteins, p107 and p130, which 
lead to the formation of the DREAM complex and the repression of gene expression. 
According to Neto et al., the high levels of p21 expression found in functional pituitary 
adenomas represents the most widespread molecular genetic alteration demonstrated in 
pituitary adenomas (Neto et al., 2005). Since, in most cases, the p53 protein is found to 
be wild-type, I think that there might be mutations of significance in the p21/CDKN1A 
gene that produces the p21 protein that might help to explain why some pituitary 














In this thesis, the data on 38 samples from 36 patients were collected, classified, 
and compartmentalized. Due to the longitudinal methods of the study, some follow-up on 
some of the patients was not able to be completed.  
From the results of the study, three samples were found to have TP53 somatic 
mutations. No tumors that secrete ACTH (functional) were found to have mutations in 
the TP53 gene. Three out of the four somatic mutations that were found produced 
nonfunctional or disrupted variants of p53 (R248Q, R175C, H214R) that have been well-
documented and verified by both ClinVar and COSMIC databases. The other somatic 
splice site mutation of p53, c.993+1G>A, which produces a disrupted or absent p53 
protein, has been documented and verified by both ClinVar and COSMIC. Along with 
mutations in the TP53 gene, somatic mutations in DAXX and ATRX were found in sample 
29 and 36, respectively, which are associated with various cancers of the body. 
Having shown that there are 2 out of the 3 identified patients in the cohort with 
silent, extremely aggressive corticotropic adenomas that also had TP53 mutations that led 
to a disrupted or absent p53 protein product, I conclude that these mutations in the TP53 
gene are responsible for the aggressiveness observed in these patients’ corticotropic 
adenomas, and there is a correlation between TP53 gene mutations that produce an 
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